WHAT IS A BIOSIMILAR?
MVASI® IS A BIOLOGIC MEDICINE CALLED A BIOSIMILAR
MVASI® (bevacizumab-awwb) is a biosimilar to Avastin®. It was shown to have similar efficacy and side effects to Avastin®.1,2
MVASI® is carefully made and tested. This is to make sure it is similar in efficacy and side effects to the existing biologic (also called the reference product).1,3
A BIOSIMILAR IS DIFFERENT THAN A GENERIC
Biosimilars are made to be almost identical to the original biologic drug. But it is not possible to make exact copies of biologics because they are made from living cells. Biosimilars are also made from living cells.3
Biosimilars go through rigorous testing to demonstrate that they provide results similar to those of the reference product.3
MVASI® is made by Amgen, which has a 40-year track record of developing biologics and bringing treatments to millions of people with cancer.
Amgen is deeply committed to supporting patients through their treatment journey. You can expect Amgen to deliver quality products on time and to provide support every step of the way.
*Current as of April 2021.
Important Safety Information
Possible serious side effects
Everyone reacts differently to MVASI® therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.
Side effects seen most often
In clinical studies across different types of cancer, some patients experienced the following side effects:
MVASI® is not for everyone
Talk to your doctor if you are:
For more information about your treatment or condition, talk to your doctor.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see full Product Information for additional Important Safety Information.
Metastatic Colorectal Cancer (mCRC)
MVASI® is approved to treat metastatic colorectal cancer (mCRC) for:
MVASI® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.
Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
MVASI®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.
Recurrent Glioblastoma (rGBM)
MVASI® is approved to treat recurrent glioblastoma in adults.
Metastatic Renal Cell Carcinoma (mRCC)
MVASI®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).
Advanced Cervical Cancer (CC)
MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.
Ovarian Cancer (OC)
MVASI®, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.
MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments.
MVASI®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
References: 1. MVASI® (bevacizumab-awwb) Prescribing Information, Amgen. 2. Thatcher N, Goldschmidt JH, Thomas M, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res. 2019;25:2088-2095. 3. US Food and Drug Administration. Biosimilars: more treatment choices and innovation.. Accessed March 2, 2020. 4. Data on file, Amgen [#1 Prescribed Bevacizumab]; 2021.